Related Experiment Videos
Vascular protection with newer antihypertensive agents
1Medical Research Council of Canada Multidisciplinary Research Group of Hypertension, Clinical Research Institute of Montreal, University of Montreal, Quebec, Canada.
Summary
Newer antihypertensive medications, including calcium antagonists and ACE inhibitors, show promise in improving small artery structure and function in hypertension. Further research is needed to confirm their impact on cardiovascular outcomes.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Hypertension Research
Background:
- Elevated blood pressure (hypertension) is linked to altered small artery structure and function, contributing to cardiovascular complications.
- Intracellular calcium plays a crucial role in vascular smooth muscle contraction, growth, and the release of vasoactive agents.
Purpose of the Study:
- To evaluate the vascular protective effects of newer antihypertensive agents that modulate intracellular calcium pathways.
- To compare the impact of angiotensin converting enzyme (ACE) inhibitors and calcium antagonists on vascular remodeling and endothelial function.
Main Methods:
- A double-blind trial compared cilazapril (ACE inhibitor) and atenolol (beta-blocker) on the media:lumen ratio of small arteries.
- Studies assessed the effects of amlodipine (calcium antagonist) on forearm minimal vascular resistance and nitric oxide synthase inhibition.
- Evaluated the impact of slow-release nifedipine on small artery structure and endothelium-dependent relaxation.
Main Results:
- Cilazapril treatment corrected the increased media:lumen ratio in hypertensive patients, unlike atenolol.
- Amlodipine reduced forearm minimal vascular resistance and normalized vascular responses to nitric oxide synthase inhibition.
- Nifedipine normalized small artery media:lumen ratio and endothelium-dependent relaxation.
Conclusions:
- Long-acting calcium antagonists and ACE inhibitors demonstrate promising vascular benefits in hypertension.
- Further clinical trials are necessary to determine if these vascular improvements translate to reduced cardiovascular morbidity and mortality.